JP2020531537A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531537A5
JP2020531537A5 JP2020511441A JP2020511441A JP2020531537A5 JP 2020531537 A5 JP2020531537 A5 JP 2020531537A5 JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020531537 A5 JP2020531537 A5 JP 2020531537A5
Authority
JP
Japan
Prior art keywords
canakinumab
dose
months
events
recurrent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020511441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/056468 external-priority patent/WO2019038740A1/en
Publication of JP2020531537A publication Critical patent/JP2020531537A/ja
Publication of JP2020531537A5 publication Critical patent/JP2020531537A5/ja
Withdrawn legal-status Critical Current

Links

JP2020511441A 2017-08-25 2018-08-24 カナキヌマブの使用 Withdrawn JP2020531537A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549971P 2017-08-25 2017-08-25
US62/549,971 2017-08-25
US201762584380P 2017-11-10 2017-11-10
US62/584,380 2017-11-10
PCT/IB2018/056468 WO2019038740A1 (en) 2017-08-25 2018-08-24 USE OF CANAKINUMAB

Publications (2)

Publication Number Publication Date
JP2020531537A JP2020531537A (ja) 2020-11-05
JP2020531537A5 true JP2020531537A5 (cg-RX-API-DMAC7.html) 2021-09-09

Family

ID=63643018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Country Status (5)

Country Link
US (3) US20200239564A1 (cg-RX-API-DMAC7.html)
EP (2) EP3710476A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020531539A (cg-RX-API-DMAC7.html)
TW (2) TW201919695A (cg-RX-API-DMAC7.html)
WO (2) WO2019038740A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210324067A9 (en) * 2018-03-09 2021-10-21 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES

Similar Documents

Publication Publication Date Title
Cannon et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
Chan et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis
Song et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs
JP2019514925A5 (cg-RX-API-DMAC7.html)
Abeles et al. Gout and cardiovascular disease: crystallized confusion
JP2017503820A5 (cg-RX-API-DMAC7.html)
JP2020531539A5 (cg-RX-API-DMAC7.html)
JP2019501226A5 (cg-RX-API-DMAC7.html)
Wong et al. Cardiovascular issues of COX-2 inhibitors and NSAIDs
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
Athyros et al. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
JP2020510045A5 (cg-RX-API-DMAC7.html)
Ye et al. Do we really need aspirin loading for STEMI?
JP2021502379A5 (cg-RX-API-DMAC7.html)
Haverkamp et al. Post-thoracotomy dysrhythmia
Chan Helicobacter pylori, NSAIDs and gastrointestinal haemorrhage
ATE432691T1 (de) Geschmackmaskierte granulierte teilchen
MX2020012609A (es) Inhibidor del hif-1?, metodo de preparacion del mismo, y composicion farmaceutica para prevenir o tratar la enfermedad ocular asociada a la angiogenesis, que contiene el mismo como ingrediente activo.
Chia et al. Beta‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, nitrate‐hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID 2): an evidence‐based mnemonic for the treatment of systolic heart failure
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
Neogi et al. Pursuit of a dual-benefit antigout drug: a first look at arhalofenate
Zeymer Oral antiplatelet therapy in acute coronary syndromes: recent developments
Quintana et al. Effect of human, dentin, albumin and lipopolysaccharide on the antibacteerial activity of endodontic activity of endodontic irrigants
Lazzaroni et al. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Perez-Ruiz et al. FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study